THE CIGNA GROUP(CI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CI THE CIGNA GROUP

Post-Market Trading 11-25 16:11:48 EST

332.95

+4.50

+1.37%

盘后333.02

+0.07+0.02%

16:10 EST

High335.08	Low330.07	Vol2.50M
Open330.68	D1 Closing328.45	Amplitude1.53%
Mkt Cap92.61B	Tradable Cap92.17B	Total Shares278.15M
T/O834.10M	T/O Rate0.90%	Tradable Shares276.83M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"CI","market":"US","secType":"STK","nameCN":"THE CIGNA GROUP","latestPrice":332.95,"timestamp":1732568399999,"preClose":328.45,"halted":0,"volume":2499374,"hourTrading":{"tag":"盘后","latestPrice":333.0233,"preClose":332.95,"latestTime":"16:10 EST","volume":201784,"amount":67196763.79856001,"timestamp":1732569021735},"delay":0,"floatShares":276828154,"shares":278152606,"eps":10.569287,"marketStatus":"Post-Market Trading","change":4.5,"latestTime":"11-25 16:11:48 EST","open":330.68,"high":335.08,"low":330.07,"amount":834104287.97472,"amplitude":0.015253,"askPrice":340.47,"askSize":52,"bidPrice":333.01,"bidSize":8,"shortable":3,"etf":0,"ttmEps":10.569287,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1732582800000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":328.45,"dividendRate":0.016309,"preHourTrading":{"tag":"盘前","latestPrice":330.18,"preClose":328.45,"latestTime":"09:29 EST","volume":270,"amount":89083.692,"timestamp":1732544992088},"postHourTrading":{"tag":"盘后","latestPrice":333.0233,"preClose":332.95,"latestTime":"16:10 EST","volume":201784,"amount":67196763.79856001,"timestamp":1732569021735},"volumeRatio":1.77503,"impliedVol":0.2315,"impliedVolPercentile":0.3492},"requestUrl":"/m/hq/s/CI/wiki","defaultTab":"wiki","newsList":[{"id":"2486304570","title":"BUZZ-CI Financial hits 9-yr high after Mubadala inks $8.7 bln take-private deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2486304570","media":"Reuters","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486304570?lang=en_us&edition=fundamental","pubTime":"2024-11-26 01:25","pubTimestamp":1732555541,"startTime":"0","endTime":"0","summary":"** Shares of Canadian asset and wealth manager CI Financial  jump 30.2% to C$31.26   ** Stock trading at its highest since October 2015   ** Abu Dhabi-based Mubadala Capital will take CIX private in a C$12.1 bln  deal - CI Financial   ** Mubadala will pay CIX shareholders C$32/shr, a 33% upside to stock's last close   ** Deal, expected to close in Q2 2025, values CI's equity at about C$4.7 bln   ** CEO Kurt MacAlpine will continue to lead CIX, which will remain headquartered in Canada    ** CIX has been a divisive name among investors, given its largely aggressive debt financed M&A expansion strategy to build its U.S. wealth management platform - Scotiabank    ** Brokerage believes the approach aligns quite well for a private equity player, adding that it sees a competing bid as a low probability   ** As of last close, CIX shares up 61.6% YTD ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","BK4588","BK4196","LU1261432733.SGD","IE00B19Z3B42.SGD","IE0002270589.USD","BK4585","LU0289739699.SGD","LU0868494617.USD","IE00B19Z3581.USD","LU1059921491.USD","CI","IE00BSNM7G36.USD"],"gpt_icon":0},{"id":"2486037648","title":"Toronto Stocks Unchanged; CI Financial Shares Jump on Buyout Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2486037648","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486037648?lang=en_us&edition=fundamental","pubTime":"2024-11-26 01:02","pubTimestamp":1732554120,"startTime":"0","endTime":"0","summary":"Toronto-listed stocks were virtually flat in midday trading Monday.Materials and energy stocks were the biggest drags in the session, offsetting gains primarily from manufacturing, finance and commercial services.An advance estimate signaled a recovery in Canadian factory trade in October, rising 1.3% in the month led by a rebound in sales of petroleum and coal products as well as increased sales of transportation equipment.Canada's S&P/TSX Composite Index was virtually flat, at 25435.33, and the blue-chip S&P/TSX 60 was also unchanged, at 1524.76.CI Financial's shares advanced by 30%, to 31.26 Canadian dollars , after the asset and wealth manager agreed to be taken private by Mubadala Capital, the asset-management arm of Abu Dhabi's sovereign wealth fund, in a deal worth C$4.7 billion.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0868494617.USD","BK4585","BK4196","LU1059921491.USD","CI","IE00BSNM7G36.USD","LU0058720904.USD","IE00B19Z3581.USD","BK4588","IE00B19Z3B42.SGD","LU0289739699.SGD","LU1261432733.SGD","IE0002270589.USD"],"gpt_icon":0},{"id":"2486032518","title":"CI Financial Takeover Multiple Seen on Low Side But Deal Expected to Close -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2486032518","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486032518?lang=en_us&edition=fundamental","pubTime":"2024-11-26 00:41","pubTimestamp":1732552860,"startTime":"0","endTime":"0","summary":"1141 ET - The takeover price for CI Financial reflects a low multiple for one of Canada's largest independent asset managers and a fast-growing U.S. business, but since the deal with an affiliate of Mubadala Capital is friendly and will see equity held by the board and management roll over it is expected to close, Raymond James' Stephen Boland says. CI shareholders will receive C$32 cash a share, a 33% premium to last Friday's closing price. Boland notes the take-private deal avoids future changes to CI's structure and leaves its leadership team intact. The analysts adds it has been three years since CI's stock traded above C$30, so the price should satisfy shareholders and insiders that may have some fatigue. ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1059921491.USD","BK4588","BK4585","IE0002270589.USD","IE00B19Z3581.USD","LU0868494617.USD","LU1261432733.SGD","BK4196","LU0289739699.SGD","LU0058720904.USD","CI","IE00B19Z3B42.SGD","IE00BSNM7G36.USD"],"gpt_icon":0},{"id":"2486039998","title":"Abu Dhabi Sovereign Wealth Affiliate to Take CI Financial Private -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2486039998","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486039998?lang=en_us&edition=fundamental","pubTime":"2024-11-25 23:49","pubTimestamp":1732549740,"startTime":"0","endTime":"0","summary":"Wealth and asset management company CI Financial has agreed to sell itself to Mubadala Capital, a unit of an Abu Dhabi sovereign wealth fund, in a deal that would take CI Financial private.Mubadala's all-cash acquisition values CI Financial's equity at approximately 4.7 billion Canadian dollars  and implies an enterprise value of approximately C$12.1 billion, the companies said Monday morning.As part of the deal, Mubadala will buy all outstanding shares of CI, which trade on the Toronto Stock Exchange, for cash consideration equal to C$32 per share. The companies say that represents a 33% premium to the last closing price prior to the announcement of the transaction and a premium of 58% to the 60-day volume-weighted average trading price.The company will maintain its current structure, management team, and Canadian headquarters, according to CI Financial. It will also remain independent of Mubadala Capital's other portfolio businesses. The acquisition is subject to certain approvals an","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CI","LU0868494617.USD","IE0002270589.USD","BK4588","LU1059921491.USD","LU0058720904.USD","IE00BSNM7G36.USD","BK4585","LU1261432733.SGD","LU0289739699.SGD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","BK4196"],"gpt_icon":0},{"id":"2486037696","title":"Here's Why Cigna (CI) is a Strong Value Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2486037696","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486037696?lang=en_us&edition=fundamental","pubTime":"2024-11-25 22:40","pubTimestamp":1732545611,"startTime":"0","endTime":"0","summary":"For new and old investors, taking full advantage of the stock market and investing with confidence are common goals.While you may have an investing style you rely on, finding great stocks is made easier with the Zacks Style Scores. These are complementary indicators that rate stocks based on value, growth, and/or momentum characteristics.Why Investors Should Pay Attention to This Value Stock. Different than growth or momentum investors, value-focused investors are all about finding good stocks at good prices, and discovering which companies are trading under what their true value is before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, and Price/Cash Flow to help pick out the most attractive and discounted stocks.Headquartered in Bloomfield, CT and formed in 1982, Cigna Corporation has rebranded itself as The Cigna Group. The company was formed as a result of a merger between Connecticut General Life Insurance Company and Insurance Comp","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/AwCmIhR0z9Bg4cEkwuNQjw--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/8442d24e11d454aa89061259a9714d43","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/AwCmIhR0z9Bg4cEkwuNQjw--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/8442d24e11d454aa89061259a9714d43"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-why-cigna-ci-strong-144011294.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B19Z3581.USD","LU0058720904.USD","LU0289739699.SGD","LU0868494617.USD","IE0002270589.USD","BK4588","BK4196","CI","BK4585","IE00B19Z3B42.SGD","LU1261432733.SGD","LU1059921491.USD","IE00BSNM7G36.USD"],"gpt_icon":0},{"id":"2486087735","title":"UAE's Mubadala agrees to take CI Financial private in $8.7B deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2486087735","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486087735?lang=en_us&edition=fundamental","pubTime":"2024-11-25 22:20","pubTimestamp":1732544459,"startTime":"0","endTime":"0","summary":"skynesher/E+ via Getty ImagesCI Financial (OTCPK:CIXXF) entered an agreement to be acquired by an affiliate of Mubadala Capital in deal that implies an enterprise value of ~C$12.1B (US $8.67B), the co","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1495019476/image_1495019476.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1495019476/image_1495019476.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4329867-mubadala-agrees-to-take-ci-financial-private","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["BK4135","LU0868494617.USD","CIXXF","BK4585","LU1059921491.USD","CI","UAE","LU1261432733.SGD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","BK4196","LU0058720904.USD","BK4588","IE0002270589.USD","IE00BSNM7G36.USD","LU0289739699.SGD"],"gpt_icon":0},{"id":"2486893350","title":"Mubadala Capital to Take Canada's CI Financial Private in C$4.7B Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2486893350","media":"Dow Jones","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486893350?lang=en_us&edition=fundamental","pubTime":"2024-11-25 21:07","pubTimestamp":1732540020,"startTime":"0","endTime":"0","summary":"An arm of Abu Dhabi's sovereign wealth fund has agreed to buy CI Financial in a deal valuing the Canadian asset and wealth manager at about 4.7 billion Canadian dollars, the equivalent of $3.4 billion.Mubadala Capital, the asset-management unit of the sovereign wealth fund, struck a definitive agreement to buy CI's for a cash consideration equal to C$32 a share, which marks a 33% premium to the last closing price. CI said the deal to take it private implies an enterprise value of close to C$12.1 billion.The takeover provides long-term capital to help fund CI's growth and its expansion in the U.S., where it operates as Corient, the Toronto-based company said. CI said that under the agreement it will retain its existing leadership and its headquarters in Canada and existing operations in the country.Hani Barhoush, managing director and chief executive of Mubadala Capital, said the firm was fully aligned with the strategy and direction of CI and aimed to support building its business.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","LU1261432733.SGD","BK4588","IE00BSNM7G36.USD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","CI","LU0058720904.USD","LU1059921491.USD","BK4196","BK4585","LU0868494617.USD","IE0002270589.USD"],"gpt_icon":0},{"id":"2486086480","title":"CI Financial to Go Private with Mubadala Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2486086480","media":"TIPRANKS","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486086480?lang=en_us&edition=fundamental","pubTime":"2024-11-25 20:49","pubTimestamp":1732538995,"startTime":"0","endTime":"0","summary":"CI Financial (TSE:CIX) has released an update. CI Financial is set to go private following a $4.7 billion all-cash offer from Mubadala Capital, whi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ci-financial-to-go-private-with-mubadala-capital?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ci-financial-to-go-private-with-mubadala-capital?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LU0868494617.USD","LU1059921491.USD","BK4588","LU0289739699.SGD","IE00B19Z3B42.SGD","IE0002270589.USD","IE00BSNM7G36.USD","CI","IE00B19Z3581.USD","BK4196","LU1261432733.SGD","LU0058720904.USD"],"gpt_icon":0},{"id":"2486918083","title":"UPDATE 1-Mubadala to take Canada's CI Financial private","url":"https://stock-news.laohu8.com/highlight/detail?id=2486918083","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486918083?lang=en_us&edition=fundamental","pubTime":"2024-11-25 20:19","pubTimestamp":1732537146,"startTime":"0","endTime":"0","summary":"(Adds deal value per share in paragraph 2)      Nov 25 (Reuters) - Mubadala Capital, Abu Dhabi's sovereign wealth fund, will take Canadian asset and wealth manager CI Financial    private in a deal th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3B42.SGD","IE00B19Z3581.USD","BK4588","LU1059921491.USD","LU0058720904.USD","LU0289739699.SGD","LU0868494617.USD","CI","IE00BSNM7G36.USD","LU1261432733.SGD","BK4196","BK4585","IE0002270589.USD"],"gpt_icon":0},{"id":"2485021277","title":"Cigna Group Stock Outperforms Competitors Despite Losses On The Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2485021277","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485021277?lang=en_us&edition=fundamental","pubTime":"2024-11-23 05:44","pubTimestamp":1732311840,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Cigna Group  slid 0.49% to $328.45 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index  rising 0.35% to 5,969.34 and the Dow Jones Industrial Average  rising 0.97% to 44,296.51.The stock's fall snapped a four-day winning streak.Cigna Group closed $42.38 below its 52-week high , which the company achieved on September 16th.The stock demonstrated a mixed performance when compared to some of its competitors Friday, as UnitedHealth Group Inc.  fell 1.11% to $590.87, CVS Health Corp.  rose 1.59% to $58.01, and Elevance Health Inc.  fell 0.26% to $402.55.Trading volume  remained 148,066 below its 50-day average volume of 1.6 M.Data source: Dow Jones Market Data, FactSet. Data compiled November 22, 2024.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jon","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CI"],"gpt_icon":0},{"id":"2485445105","title":"Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & More","url":"https://stock-news.laohu8.com/highlight/detail?id=2485445105","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485445105?lang=en_us&edition=fundamental","pubTime":"2024-11-22 01:13","pubTimestamp":1732209180,"startTime":"0","endTime":"0","summary":"The focus shifts back to regualr pipleine updates in the biotech sector with the end of the third-quarter earnings season. Among these, Sage Therapeutics, Inc. SAGE and Incyte INCY were in focus this week as investors were disappointed with study failures.Sage Therapeutics announced disppointing top-line results from the mid-stage study on dalzanemdor . The phase II DIMENSION Study was a 12-week, double-blind, placebo-controlled study to evaluate the effects of dalzanemdor in participants with cognitive impairment  associated with Huntington’s Disease . A total of 189 participants were randomized.However, the study did not demonstrate a statistically significant difference from baseline in participants treated with dalzanemdor versus placebo on the Symbol Digit Modalities Test , a measure of cognitive function, at day 84, the primary endpoint.SAGE will also discontinue the ongoing PURVIEW Study, an open-label safety study of dalzanemdor in participants with HD.PYX-201 achieved a confir","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/1H9NqoSNLfLtMd2fyMlfBA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9883d206905e7516b2353476e213e60c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/1H9NqoSNLfLtMd2fyMlfBA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9883d206905e7516b2353476e213e60c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biotech-stock-roundup-sage-incy-171300122.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BJT1NW94.SGD","LU0985320562.USD","LU0203345920.USD","LU1066051811.HKD","BK4588","PYXS","LU0238689110.USD","BTC","LU2461242641.AUD","LU2023250504.SGD","LU0289739699.SGD","LU1917777945.USD","MRK","IE0002141913.USD","BK4559","INCY","LU1989771016.USD","BK4585","IE0002270589.USD","LU0868494617.USD","LU1061106388.HKD","LU0070302665.USD","IE00BSNM7G36.USD","LU1093756168.USD","LU0109394709.USD","SG9999001176.USD","LU1291159041.SGD","CI","SAGE","SG9999014559.SGD","LU0965509283.SGD","LU1941712348.USD","LU2361045086.USD","IE00B19Z3581.USD","SG9999002232.USD","SG9999002224.SGD","BK4533","LU1989772923.USD","JAZZ","LU1066051498.USD","LU1116320737.USD","LU1059921491.USD","LU2112291526.USD","LU1989772840.SGD","LU1093756325.SGD","SG9999014542.SGD","IE0009355771.USD","LU0211331839.USD","LU0203347892.USD","IE00BLSP4452.SGD"],"gpt_icon":0},{"id":"2485410617","title":"SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2485410617","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485410617?lang=en_us&edition=fundamental","pubTime":"2024-11-21 23:56","pubTimestamp":1732204560,"startTime":"0","endTime":"0","summary":"Sage Therapeutics’ SAGE phase II study evaluating its neuropsychiatric candidate, dalzanemdor , for treating cognitive impairment  associated with Huntington’s Disease  failed to meet the primary endpoint.The double-blind, placebo-controlled DIMENSION study evaluated the effects of dalzanemdor in participants with CI associated with HD.Top-line data from the study showed that dalzanemdor failed to demonstrate a statistically significant difference from baseline compared to placebo on the Symbol Digit Modalities Test, a measure of cognitive function, at day 84. This was the primary endpoint of the study.The stock hit its 52-week low on the pipeline setback. Year to date, shares of Sage Therapeutics have plunged 77.3% compared with the industry’s decline of 8.5%.An inherited disorder, HD, causes nerve cells  in brain parts to gradually break down and die. CI is one of the most under-recognized aspects of HD. Currently, no treatment options are available to improve HD-related cognitive ef","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/b7YQi_HTDu1GkQZqPUqgyw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/b7YQi_HTDu1GkQZqPUqgyw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sages-dalzanemdor-fails-meet-goal-155600924.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0942090050.USD","IMCR","LU1169589451.USD","LU2756315318.SGD","CSTL","LU0820562030.AUD","LU0079474960.USD","SPRO","LU1778281490.HKD","IE00B1XK9C88.USD","MCI","BK4581","IE00B19Z3B42.SGD","LU1674673428.USD","SAGE","LU0823434583.USD","BK4023","BK4083","LU0689472784.USD","IE00BWXC8680.SGD","IE0002270589.USD","LU2756315664.SGD","BK4139","LU0820561909.HKD","BK4588","BK4550","BK4567","BK4585","LU0354030511.USD","LU1162221912.USD","LU1093756325.SGD","LU1169590202.USD","BK4196","BK4505","BK4566","CI","LU1551013425.SGD","PD","LU0943347566.SGD","LU0058720904.USD","LU0823411888.USD","LU1035775433.USD","LU1551013342.USD","BK4504","HD","IE00BSNM7G36.USD","LU0234572021.USD","SG9999001440.SGD","LU0823434740.USD","BK4533"],"gpt_icon":0},{"id":"2485510948","title":"Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2485510948","media":"PR Newswire","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485510948?lang=en_us&edition=fundamental","pubTime":"2024-11-21 08:19","pubTimestamp":1732148340,"startTime":"0","endTime":"0","summary":"Ziihera is the first and only dual HER2-targeted bispecific antibody approved for HER2+ BTC in the U.S.Ziihera received accelerated approval based on results including a 52% objective response rate and median duration of response of 14.9 months as determined by independent central review  from the HERIZON-BTC-01 clinical trial. The FDA approval of Ziihera is based on compelling data from the HERIZON-BTC-01 trial, which included the evaluation of zanidatamab as a single agent in previously treated HER2-positive  BTC and is the largest Phase 2b clinical trial to date specifically for this patient population. The trial achieved its primary endpoint of confirmed objective response rate  by independent central review  and results were presented at the American Society of Clinical Oncology  Annual Meeting 2023,published in The Lancet Oncology,and included in the 2023 Best of","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/JlAZfc0NY41AU1qFnWFkeg--~B/aD0yODg7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/978aa3435328e1c4e67d713d9059317d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/JlAZfc0NY41AU1qFnWFkeg--~B/aD0yODg7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/978aa3435328e1c4e67d713d9059317d"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/jazz-pharmaceuticals-announces-u-fda-001900650.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/jazz-pharmaceuticals-announces-u-fda-001900650.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4533","IE00B19Z3581.USD","LU0109394709.USD","LU0868494617.USD","BTC","BK4585","IE0002270589.USD","LU0058720904.USD","IE00B19Z3B42.SGD","JAZZ","BK4532","BK4196","IHC","LU0320765992.SGD","BK4588","LU0889565916.HKD","BK4007","IE00BSNM7G36.USD","CI","BK4162","LU1059921491.USD","LU0289739699.SGD","CDC","LU1261432733.SGD"],"gpt_icon":0},{"id":"2485767931","title":"Cigna Group Stock Underperforms Wednesday When Compared To Competitors Despite Daily Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=2485767931","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485767931?lang=en_us&edition=fundamental","pubTime":"2024-11-21 05:44","pubTimestamp":1732139040,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Cigna Group  inched 0.28% higher to $323.39 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index  remaining mostly unchanged at 5,917.11 and the Dow Jones Industrial Average  rising 0.32% to 43,408.47.This was the stock's third consecutive day of gains.Cigna Group closed $47.44 below its 52-week high , which the company achieved on September 16th.The stock underperformed when compared to some of its competitors Wednesday, as UnitedHealth Group Inc.  rose 4.07% to $600.50, CVS Health Corp.  rose 1.90% to $56.83, and Elevance Health Inc.  rose 0.83% to $397.48.Trading volume  remained 52,250 below its 50-day average volume of 1.6 M.Data source: Dow Jones Market Data, FactSet. Data compiled November 20, 2024.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently f","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CI"],"gpt_icon":0},{"id":"2485369121","title":"Dr. Oz Goes from TV to the Most Important Job in Healthcare. Here's What CMS Actually Does. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2485369121","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485369121?lang=en_us&edition=fundamental","pubTime":"2024-11-21 03:09","pubTimestamp":1732129740,"startTime":"0","endTime":"0","summary":"President-elect Donald Trump's announcement late Tuesday that he would appoint Dr. Mehmet Oz as administrator of the Centers for Medicare and Medicaid Services puts a man best known for hosting a television talk show into what might be the most important job in the U.S. healthcare system.The CMS administrator is not the most high-profile health official in any presidential administration. The current administrator, Chiquita Brooks-LaSure, is far from a household name. The post is, however, enormously consequential. It touches nearly every healthcare provider, healthcare institution, and healthcare company in the country. It has a direct hand in the care of nearly half of all Americans through the insurance programs it funds or operates.Oz, a surgeon with an MD and an M.B.A. from the University of Pennsylvania, is best known for hosting \"The Dr. Oz Show,\" a daytime television program where for years presented health cures that were often not backed by evidence.\"There's an unending amoun","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B894F039.SGD","JNJ","LU1244550577.SGD","LU1496350502.SGD","LU1720051108.HKD","LU0345770308.USD","LU0211326755.USD","IE00BFSS7M15.SGD","LU0390134368.USD","IE00B2B36J28.USD","BK4100","LU0354030511.USD","LU1196500208.SGD","HCSG","IE00B7SZLL34.SGD","IE00B19Z3B42.SGD","LU0320765646.SGD","BK4137","LU0203347892.USD","SGXZ57979304.SGD","LU1551013342.USD","LU1983299246.USD","IE0034235303.USD","LU0203345920.USD","LU0077335932.USD","CMS","LU2360032135.SGD","LU0456855351.SGD","LU2491050154.USD","UNH","LU0868494617.USD","LU1066051498.USD","LU2089284900.SGD","SG9999001176.USD","LU1023059063.AUD","LU0795875086.SGD","IE00B19Z8W00.USD","SG9999018857.SGD","LU2271345857.HKD","HUM","LU0683600562.USD","CI","LU1854104046.USD","IE00B4R5TH58.HKD","LU1037948897.HKD","LU0211331839.USD","TV","LU1032466523.USD","LU0348723411.USD"],"gpt_icon":0},{"id":"2484146147","title":"After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2484146147","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484146147?lang=en_us&edition=fundamental","pubTime":"2024-11-20 23:36","pubTimestamp":1732116973,"startTime":"0","endTime":"0","summary":"On Wednesday, Sage Therapeutics Inc revealed topline results from the Phase 2 DIMENSION Study of dalzanemdor  in participants with cognitive impairment  associated with Huntington’s Disease , an inherited brain disorder that causes nerve cells in the brain to break down and die.In the study, dalzanemdor did not demonstrate a statistically significant difference versus placebo on the primary endpoint, the change from baseline on the Symbol Digit Modalities Test  at Day 84.Also Read: After Series Of Trial Setbacks, Sage Therapeutics To Lay Off One-Third Workforce. SDMT is used for cognitive evaluation, and measures sustained attention, processing speed, visual scanning, and motor speed.Based on these results, the company does not plan to develop dalzanemdor further.In October, Sage Therapeutics released topline results from the Phase 2 LIGHTWAVE study to evaluate the effects of dalzanemdor  in participants with mild cognitive impairment  or mild dementia due toAlzheimer's Disease .This a","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/XyFKzp6muhv8s2xUnRZDfw--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/8af048e53d820bdd0358bcf43d65195c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/XyFKzp6muhv8s2xUnRZDfw--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/8af048e53d820bdd0358bcf43d65195c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/failed-alzheimers-study-sage-therapeutics-153613183.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4534","BK4083","BK4585","LU0820561909.HKD","LU0820562030.AUD","LU1674673428.USD","MCI","LU0942090050.USD","LU1093756325.SGD","LU0943347566.SGD","LU0823434583.USD","BK4581","LU0354030438.USD","LU1989772840.SGD","IE00BKVL7J92.USD","LU1551013425.SGD","LU1778281490.HKD","IE00B19Z3B42.SGD","LU1674673691.USD","LU1929549753.HKD","IE0002270589.USD","LU0689472784.USD","LU1261432733.SGD","LU0234572021.USD","LU1059921491.USD","SG9999001440.SGD","BK4139","BK4504","HD","LU1069344957.HKD","IE00BSNM7G36.USD","LU1496350171.SGD","IE00BZ1G4Q59.USD","IE00BWXC8680.SGD","IE00B1XK9C88.USD","BK4196","LU1989772923.USD","CI","BK4567","LU1496350502.SGD","IE00B19Z3581.USD","BK4550","SAGE","LU1093756168.USD","BK4566","LU0868494708.USD","LU0289739699.SGD","LU0079474960.USD","LU2756315664.SGD","LU0320765646.SGD"],"gpt_icon":0},{"id":"2484110085","title":"CVS, OptumRx, Express sue FTC over insulin cost case, Bloomberg Law says","url":"https://stock-news.laohu8.com/highlight/detail?id=2484110085","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484110085?lang=en_us&edition=fundamental","pubTime":"2024-11-20 22:41","pubTimestamp":1732113700,"startTime":"0","endTime":"0","summary":"The three largest pharmacy benefit managers in the U.S., CVS Caremark (CVS), UnitedHealth’s (UNH) OptumRx, and Cigna’s (CI) Express Scripts, have f...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cvs-optumrx-express-sue-ftc-over-insulin-cost-case-bloomberg-law-says?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cvs-optumrx-express-sue-ftc-over-insulin-cost-case-bloomberg-law-says?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2089284900.SGD","CVS","LU1267930573.SGD","LU0738911758.USD","LU1791710400.SGD","LU0289739699.SGD","LU0496365809.HKD","SG9999013999.USD","LU0320765059.SGD","FTC","LU1814569148.SGD","LU0820561909.HKD","LU1066051498.USD","LU1074936037.SGD","LU2023251221.USD","LU2357305700.SGD","LU0097036916.USD","LU0708995401.HKD","LU1548497426.USD","IE00BJJMRX11.SGD","SG9999014906.USD","LU1674673691.USD","LU0795875169.SGD","LU0342679015.USD","LU0683600562.USD","LU2211815571.USD","LU2236285917.USD","SG9999002224.SGD","LU2324357040.USD","IE00BKVL7J92.USD","LU0149725797.USD","LU0949170772.SGD","LU2360032135.SGD","LU0557290698.USD","LU0345770308.USD","LU0203347892.USD","LU0310800379.SGD","IE00B4JS1V06.HKD","LU0256863811.USD","LU2125154935.USD","LU1778281490.HKD","CI","IE00BFSS8Q28.SGD","LU1267930730.SGD","UNH","LU2087625088.SGD","BK4585","LU0058720904.USD","LU0011850046.USD","LU0211326755.USD"],"gpt_icon":0},{"id":"2484944331","title":"Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2484944331","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484944331?lang=en_us&edition=fundamental","pubTime":"2024-11-20 19:30","pubTimestamp":1732102200,"startTime":"0","endTime":"0","summary":"The Phase 2 DIMENSION Study did not meet its primary endpoint. Dalzanemdor was generally well-tolerated; no new safety signals were observed. Based on these data, the Company does not plan further development of dalzanemdor. CAMBRIDGE, Mass., November 20, 2024----Sage Therapeutics, Inc.  today announced topline results from the Phase 2 DIMENSION Study of dalzanemdor  in participants with cognitive impairment  associated with Huntington’s Disease . In the study, dalzanemdor did not demonstrate a statistically significant difference versus placebo on the primary endpoint, the change from baseline on the Symbol Digit Modalities Test  at Day 84. Analyses of secondary endpoints did not demonstrate statistically significant or clinically meaningful differences in participants treated with dalzanemdor compared to placebo. Based on these results, the Company does not plan further development of dalzanemdor.\"We are disappointed by the results of the DIMENSION Study, especially for the individua","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/jlqGxr4P6ViRdaWAih_NWg--~B/aD0xMzg3O3c9NDQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/8cccd96bb5295af2aa0755b54379f770","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/jlqGxr4P6ViRdaWAih_NWg--~B/aD0xMzg3O3c9NDQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/8cccd96bb5295af2aa0755b54379f770"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sage-therapeutics-announces-topline-results-113000535.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4567","LU1929549753.HKD","IE00B19Z3B42.SGD","LU0942090050.USD","LU2756315318.SGD","LU1551013425.SGD","IE00BKVL7J92.USD","LU2756315664.SGD","SAGE","IE00BZ1G4Q59.USD","LU0320765646.SGD","LU0820561909.HKD","LU0868494708.USD","BK4566","IE00BWXC8680.SGD","LU0823434740.USD","SG9999001440.SGD","HD","LU0823411888.USD","BK4196","LU1674673428.USD","LU0868494617.USD","LU1989772840.SGD","LU1261432733.SGD","BK4139","LU0823434583.USD","LU0354030438.USD","LU0079474960.USD","LU0820561818.USD","LU0058720904.USD","LU0689472784.USD","IE00B1XK9C88.USD","IE00B19Z3581.USD","BK4533","CI","LU1162221912.USD","LU1496350171.SGD","LU1496350502.SGD","LU0354030511.USD","IE00BSNM7G36.USD","BK4550","BK4585","LU0820562030.AUD","LU1093756168.USD","LU0943347566.SGD","BK4534","BK4504","BK4083","LU1035775433.USD","LU1778281490.HKD"],"gpt_icon":0},{"id":"2484904515","title":"Cigna, CVS, UnitedHealth PBMs sue FTC over insulin prices case","url":"https://stock-news.laohu8.com/highlight/detail?id=2484904515","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484904515?lang=en_us&edition=fundamental","pubTime":"2024-11-20 06:09","pubTimestamp":1732054143,"startTime":"0","endTime":"0","summary":"FinkAvenue/iStock Editorial via Getty ImagesPharmacy benefit managers owned by Cigna , CVS Heath , and UnitedHealth Group  have sued the Federal Trade Commission, arguing that a case the agency has filed against them regarding inflated insulin prices is unconstitutional. The lawsuit was filed","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1384455170/image_1384455170.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1384455170/image_1384455170.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4309353-cigna-cvs-unitedhealth-pbms-sue-ftc-insulin-prices-case","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["LU0496365809.HKD","LU2087625088.SGD","BK4534","LU1064131342.USD","LU1153585028.USD","LU0058720904.USD","LU0545039389.USD","IE00BZ9MQY76.HKD","LU1059921491.USD","IE00B775H168.HKD","SG9999002224.SGD","LU0320765059.SGD","IE00BJJMRZ35.SGD","CVS","LU0234572021.USD","LU0122379950.USD","LU1720051108.HKD","BK4581","LU1267930573.SGD","LU2279689827.SGD","LU2362541513.USD","LU1989771016.USD","LU0456855351.SGD","LU0943347566.SGD","LU1003077747.HKD","LU0149725797.USD","IE00BZ1G4Q59.USD","LU0256863811.USD","LU0689472784.USD","LU1084165304.USD","LU1732799900.SGD","IE00B1BXHZ80.USD","UNH","LU1261432733.SGD","LU2125154778.USD","BK4532","CI","LU0029864427.USD","SG9999001176.SGD","IE00B19Z3B42.SGD","BK4504","LU0708994859.HKD","LU0079474960.USD","LU0342679015.USD","LU0708995401.HKD","IE00BJJMRX11.SGD","BK4566","LU0795875086.SGD","LU1934455863.HKD","IE00B19Z8X17.USD"],"gpt_icon":0},{"id":"2484156907","title":"Top Research Reports for Eli Lilly, PepsiCo & Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2484156907","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484156907?lang=en_us&edition=fundamental","pubTime":"2024-11-20 05:18","pubTimestamp":1732051080,"startTime":"0","endTime":"0","summary":"However, declining sales of Trulicity, rising pricing pressure on some drugs and potential competition in the GLP-1 diabetes/obesity market are some top-line headwinds.PepsiCo’s shares have underperformed the Zacks Beverages – Soft drinks industry over the past year . The Zacks analyst believes that largely due to challenges in its North American operations since the start of 2024 that includes reduced consumer demand and product recalls in the QFNA segment, the company has underperformed over the past year. Additionally, adverse currency rates continue to pose challenges.Yet, it is well-poised to benefit from strength and resilience in core categories, diversified portfolio, modernized supply chain, improved digital capabilities and flexible go-to-market distribution systems. The company's international business continues to hallmark its overall performance.Other noteworthy reports we are featuring today include Alibaba Group Holding Ltd. , The Walt Disney Co.  and Trane Technologies ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/_9OKqED6rOANF8VtUei37A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/_9OKqED6rOANF8VtUei37A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/top-research-reports-eli-lilly-211800630.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BABA","DIS","PEP","MS","TT","HBBD.SI","CI","LLY"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.thecignagroup.com","stockEarnings":[{"period":"1week","weight":0.0216},{"period":"1month","weight":0.0343},{"period":"3month","weight":-0.0721},{"period":"6month","weight":-0.0125},{"period":"1year","weight":0.1392},{"period":"ytd","weight":0.0968}],"compareEarnings":[{"period":"1week","weight":0.0167},{"period":"1month","weight":0.0303},{"period":"3month","weight":0.0594},{"period":"6month","weight":0.1248},{"period":"1year","weight":0.3088},{"period":"ytd","weight":0.2529}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers. The company's Cigna Healthcare segment offers medical, pharmacy, behavioral health, dental, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as individual health insurance plans; and health care coverage in its international markets, as well as health care benefits for mobile individuals and employees of multinational organizations. The company also offers permanent insurance contracts sold to corporations to provide coverage on the lives of certain employees for financing employer-paid future benefit obligations. It distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was formerly known as Cigna Corporation and changed its name to The Cigna Group in February 2023. The Cigna Group was founded in 1792 and is headquartered in Bloomfield, Connecticut.","yearOnYearQuotes":[{"month":1,"riseRate":0.642857,"avgChangeRate":0.018602},{"month":2,"riseRate":0.571429,"avgChangeRate":0.009544},{"month":3,"riseRate":0.595238,"avgChangeRate":0.016882},{"month":4,"riseRate":0.536585,"avgChangeRate":0.002534},{"month":5,"riseRate":0.595238,"avgChangeRate":0.019148},{"month":6,"riseRate":0.627907,"avgChangeRate":0.006999},{"month":7,"riseRate":0.348837,"avgChangeRate":-0.008751},{"month":8,"riseRate":0.627907,"avgChangeRate":0.025016},{"month":9,"riseRate":0.465116,"avgChangeRate":-0.011042},{"month":10,"riseRate":0.581395,"avgChangeRate":-0.001156},{"month":11,"riseRate":0.744186,"avgChangeRate":0.045318},{"month":12,"riseRate":0.547619,"avgChangeRate":0.022806}],"exchange":"NYSE","name":"THE CIGNA GROUP","nameEN":"THE CIGNA GROUP"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"THE CIGNA GROUP(CI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest THE CIGNA GROUP(CI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"THE CIGNA GROUP,CI,THE CIGNA GROUP股票,THE CIGNA GROUP股票老虎,THE CIGNA GROUP股票老虎国际,THE CIGNA GROUP行情,THE CIGNA GROUP股票行情,THE CIGNA GROUP股价,THE CIGNA GROUP股市,THE CIGNA GROUP股票价格,THE CIGNA GROUP股票交易,THE CIGNA GROUP股票购买,THE CIGNA GROUP股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"THE CIGNA GROUP(CI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest THE CIGNA GROUP(CI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction